In this context, Aoto et al. [7] reported that treatment with chemotherapeutic agents could trigger the release of the high-mobility group box 1 protein (HMGB1), a toll-like receptor 4 (TLR4) ligand, with subsequent induction of potent tumor antigen-specific T cell immunity. The gene discussed is TLR4; the disease is neoplasm.